Deans' stroke musings: PathMaker begins MyoRegulator trial to treat post-stroke spasticity

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, March 11, 2022

PathMaker begins MyoRegulator trial to treat post-stroke spasticity

While spasticity of my leg and foot are problems I would prefer fixing the spasticity of my hand first.

You'll have to ask your doctor what happened to riluzole for treating spasticity. Phase II clinical trials were supposed to be completed in 2018.

riluzole (5 posts to April 2013)

PathMaker begins MyoRegulator trial to treat post-stroke spasticity

The trial will assess the safety and efficacy of post-stroke lower-limb spasticity treatment with MyoRegulator.

PathMaker Neurosystems has commenced the multi-centre clinical trial of MyoRegulator for the non-invasive treatment of post-stroke spasticity in the US.

The non-invasive neuromodulation device is designed to suppress hyperexcitable spinal motor neurons.

It uses the company’s DoubleStim technology, which enables simultaneous stimulation at spinal and peripheral sites.

The randomised, sham-controlled, multi-centre, double-blind clinical trial is designed to assess the safety and efficacy of post-stroke lower-limb spasticity treatment with MyoRegulator in sham-treated and active participants.

It is being conducted with the Spaulding Rehabilitation Hospital in Charlestown, Massachusetts, and is expected to recruit 76 subjects.

The National Institute of Neurological Disorders and Stroke (NINDS) is providing a $4.9m NINDS Cooperative Research to Enable and Advance Translational Enterprises for Devices (CREATE Devices) grant for the pivotal clinical study.

Outsourcing your wire components for stimulation therapy

PathMaker CEO and president Nader Yaghoubi said: “The launch of this multi-centre trial is an important milestone in the development of our first-in-class product, MyoRegulator.

“We are very

pleased to be working with the world-class team at Spaulding, and are grateful to have the support of NINDS as we advance this product towards commercial launch.”

MyoRegulator is claimed to be the first and only neuromodulation device developed to treat muscle spasticity without using drugs or surgery.